| Literature DB >> 22529302 |
J P Daniels1, L J Middleton, R Champaneria, K S Khan, K Cooper, B W J Mol, S Bhattacharya.
Abstract
OBJECTIVE: To determine the relative effectiveness of second generation ablation techniques in the treatment of heavy menstrual bleeding.Entities:
Mesh:
Year: 2012 PMID: 22529302 PMCID: PMC3339574 DOI: 10.1136/bmj.e2564
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Characteristics of included trials and event rates for amenorrhoea, heavy bleeding, and dissatisfaction in systematic review and network meta-analysis of second generation endometrial destruction techniques for heavy menstrual bleeding
| Study | Primary outcome measure | Treatment device (manufacturer/trade name) | Amenorrhoea rate | Heavy bleeding rate | Dissatisfaction rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2nd generation | 1st generation | 2nd generation | 1st generation | 2nd generation | 1st generation | |||||
| Clark 201131 | Amenorrhoea rate | Bipolar radio frequency (NovaSure) | 14/25 | — | 2/25 | — | 2/28 | — | ||
| Thermal balloon (Thermachoice) | 6/26 | — | 6/26 | — | 6/32 | — | ||||
| Penninx 201032 | Amenorrhoea rate | Bipolar radio frequency (NovaSure) | 35/75 | — | 8/75 | — | 1/75 | — | ||
| Free fluid (BEI Medical Systems) | 17/71 | — | 10/71 | — | 10/71 | |||||
| Sambrook 200933 | Satisfaction rate | Microwave (Microsulis) | 61/149 | — | 6/149 | — | 35/144 | — | ||
| Thermal balloon (Thermachoice) | 51/134 | — | 7/134 | — | 31/134 | — | ||||
| Bongers 200434 | Amenorrhoea rate | Biploar radio frequency (NovaSure) | 34/79 | — | 14/79 | — | 8/83 | — | ||
| Thermal balloon (Thermachoice) | 3/38 | — | 7/38 | — | 8/43 | — | ||||
| Abbott 200335 | Amenorrhoea rate | Biploar radio frequency (NovaSure) | 16/37 | — | 5/37 | — | 0/34 | — | ||
| Thermal balloon (Cavaterm) | 2/17 | — | 0/17 | — | 1/15 | — | ||||
| Brun 200636 | Amenorrhoea rate | Thermal balloon (Cavaterm) | 11/30 | 5/17 | 2/30 | 2/17 | 2/21 | 3/16 | ||
| Cooper 200437 | Heavy bleeding rate | Microwave (Microsulis) | 120/194 | 49/96 | 5/194 | 5/96 | 3/196 | 1/97 | ||
| Perino 200416 | Amenorrhoea rate | Laser (ELITT) | 35/56 | 14/55 | 2/56 | 4/55 | 3/56 | 5/55 | ||
| Duleba 200317 | Heavy bleeding rate | Cryoablation (HerOption) | 43/156 | 40/72 | 19/156 | 5/72 | 16/156 | 10/72 | ||
| Hawe 200338 | Amenorrhoea rate | Thermal balloon (Cavaterm) | 10/30 | 13/28 | 1/30 | 1/28 | 2/30 | 1/28 | ||
| Van Zon-Rabelink 200339 | Heavy bleeding rate | Thermal balloon (Thermachoice) | 6/74 | 4/55 | 23/74 | 19/55 | 15/75* | 13/58* | ||
| Cooper 200214 | Heavy bleeding rate | Biploar radio frequency (NovaSure) | 63/154 | 29/82 | 14/154 | 10/82 | 11/154 | 5/82 | ||
| Pellicano 200240 | Satisfaction rate | Thermal balloon (Cavaterm) | NA | NA | NA | NA | 7/37 | 14/38 | ||
| Corson 200115 | Heavy bleeding rate | Free fluid (BEI Medical Systems) | 65/172 | 43/83 | 31/172 | 12/83 | NA | NA | ||
| Soysal 200141 | Heavy bleeding rate | Thermal balloon (Thermachoice) | 5/45 | 8/48 | 11/45 | 10/48 | 15/45 | 19/48 | ||
| Corson 200042 | Heavy bleeding rate | Thermal balloon (Vesta) | 38/122 | 39/112 | 16/122 | 19/112 | NA | NA | ||
| Cooper 199912 | Satisfaction rate | Microwave (Microsulis) | 46/116 | 48/124 | 9/116 | 11/124 | 27/116 | 32/124 | ||
| Meyer 19989 | Heavy bleeding rate | Thermal balloon (Thermachoice) | 18/122 | 32/117 | 18/122 | 13/117 | 5/122 | 1/116 | ||
| Romer 199843 | Not stated | Thermal balloon (Cavaterm) | 4/10 | 3/10 | 0/10 | 0/10 | NA | NA | ||
NA=not applicable (outcome not measured).
*Data from 24 months after randomisation but considered as 12 month data. All other data are follow-up data at 12 months after randomisation.

Fig 1 Study selection process for systematic review and network meta-analysis of second generation endometrial destruction techniques for heavy menstrual bleeding

Fig 2 Network of studies evaluating second generation endometrial destruction devices for treatment of heavy menstrual bleeding. Number of women randomised to second generation treatment are shown in parentheses
Amenorrhoea rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95% confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
| Thermal balloon | Bipolar radio frequency | Microwave | Cryoablation | Free fluid | Laser | |
|---|---|---|---|---|---|---|
| Direct | 0.72 (0.52 to 1.01); P=0.06* | 1.27 (0.73 to 2.20); P=0.4† | 1.28 (0.90 to 1.83); P=0.2‡ | 0.30 (0.17 to 0.55); P<0.001† | 0.57 (0.33 to 0.96); P=0.03† | 4.88 (2.17 to 11.00); P<0.001† |
| Network | 0.69 (0.49 to 0.97); P=0.03 | 1.73 (1.07 to 2.78); P=0.03 | 1.14 (0.73 to 1.79); P=0.5 | 0.35 (0.17 to 0.75); P=0.01 | 0.62 (0.34 to 1.13); P=0.1 | 4.36 (1.82 to 10.44); P=0.002 |
| Direct | — | 4.56 (2.24 to 9.26); P<0.001* | 1.13 (0.70 to 1.82); P=0.6† | NA | NA | NA |
| Network | — | 2.51 (1.53 to 4.12); P<0.001 | 1.66 (1.01 to 2.71); P=0.05 | 0.51 (0.23 to 1.17); P=0.1 | 0.91 (0.48 to 1.73); P=0.7 | 6.34 (2.50 to 16.07); P<0.001 |
| Direct | — | — | NA | NA | 0.36 (0.18 to 0.73); P=0.005† | NA |
| Network | — | — | 0.66 (0.36 to 1.21); P=0.2 | 0.20 (0.09 to 0.49); P=0.002 | 0.36 (0.19 to 0.67); P=0.004 | 2.52 (0.95 to 6.71); P=0.06 |
| Direct | — | — | — | NA | NA | NA |
| Network | — | — | — | 0.31 (0.13 to 0.74); P=0.01 | 0.55 (0.27 to 1.13); P=0.09 | 3.82 (1.46 to 10.01); P=0.009 |
| Direct | — | — | — | — | NA | NA |
| Network | — | — | — | — | 1.77 (0.69 to 4.58); P=0.2 | 12.37 (3.96 to 38.59); P<0.001 |
| Direct | — | — | — | — | — | NA |
| Network | — | — | — | — | — | 6.98 (2.48 to 19.69); P<0.001 |
NA=not available.
*I2=0%.
†I2=not applicable, only one study in comparison.
‡I2=17%.
Heavy bleeding rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95% confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
| Thermal balloon | Bipolar radio frequency | Microwave | Cryoablation | Free fluid | Laser | |
|---|---|---|---|---|---|---|
| Direct | 0.97 (0.66 to 1.41); P=0.9* | 0.72 (0.30 to 1.70); P=0.5† | 0.71 (0.34 to 1.50); P=0.4* | 1.86 (0.67 to 5.19); P=0.2† | 1.30 (0.63 to 2.69); P=0.5† | 0.47 (0.08 to 2.69); P=0.4† |
| Network | 0.98 (0.69 to 1.39); P=0.9 | 0.95 (0.56 to 1.62); P=0.8 | 0.59 (0.32 to 1.09); P=0.09 | 1.55 (0.63 to 3.81); P=0.3 | 1.37 (0.74 to 2.51); P=0.3 | 0.39 (0.07 to 2.09); P=0.3 |
| Direct | — | 1.02 (0.46 to 2.29); P=1.0* | 0.76 (0.25 to 2.32); P=0.6† | NA | NA | NA |
| Network | — | 0.82 (0.47 to 1.44); P=0.5 | 0.62 (0.32 to 1.18); P=0.1 | 1.62 (0.62 to 4.24); P=0.3 | 1.80 (0.90 to 3.57); P=0.09 | 0.41 (0.07 to 2.27); P=0.3 |
| Direct | — | — | NA | NA | 4.88 (1.32 to 18.11); P=0.02† | NA |
| Network | — | — | 0.75 (0.34 to 1.66); P=0.5 | 1.98 (0.70 to 5.60); P=0.2 | 2.19 (1.07 to 4.50); P=0.03 | 0.50 (0.09 to 2.89); P=0.4 |
| Direct | — | — | — | NA | NA | NA |
| Network | — | — | — | 2.63 (0.89 to 7.78); P=0.08 | 2.91 (1.23 to 6.88); P=0.02 | 0.66 (0.11 to 3.96); P=0.6 |
| Direct | — | — | — | — | NA | NA |
| Network | — | — | — | — | 1.11 (0.37 to 3.29); P=0.9 | 0.25 (0.04 to 1.70); P=0.2 |
| Direct | — | — | — | — | — | NA |
| Network | — | — | — | — | — | 0.23 (0.04 to 1.36); P=0.1 |
NA=not available.
*I2=0%.
†I2=not applicable, only one study in comparison.

Fig 3 Amenorrhoea rate at 12 months from network meta-analysis (odds ratio and 95% confidence intervals). Results reflect those in table 2 (*indicates reversed ratios so all are pointing in direction of increased amenorrhoea rate). Only results with P≤0.05 are shown
Dissatisfaction rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95% confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
| Thermal balloon | Bipolar radio frequency | Microwave | Cryoablation | Free fluid | Laser | |
|---|---|---|---|---|---|---|
| Direct | 0.80 (0.50 to 1.27); P=0.3* | 1.18 (0.40 to 3.53); P=0.8† | 0.90 (0.51 to 1.60); P=0.7‡ | 0.71 (0.30 to 1.65); P=0.4† | NA | 0.57 (0.13 to 2.49); P=0.5† |
| Network | 0.91 (0.61 to 1.36); P=0.6 | 0.51 (0.25 to 1.01); P=0.05 | 0.93 (0.59 to 1.47); P=0.7 | 0.93 (0.59 to 1.47); P=0.7 | 3.14 (0.66 to 14.83); P=0.1 | 0.54 (0.12 to 2.43) P=0.4 |
| Direct | — | 0.39 (0.16 to 0.91); P=0.03‡ | 1.07 (0.61 to 1.86); P=0.8† | NA | NA | NA |
| Network | — | 0.56 (0.28 to 1.09); P=0.09 | 1.02 (0.65 to 1.60); P=0.9 | 0.79 (0.31 to 2.05); P=0.6 | 2.66 (0.55 to 12.96); P=0.2 | 0.59 (0.12 to 2.78); P=0.5 |
| Direct | — | — | NA | NA | 9.40 (1.14 to 77.18); P=0.04† | NA |
| Network | — | — | 1.83 (0.85 to 3.95); P=0.1 | 1.42 (0.47 to 4.29); P=0.5 | 4.79 (1.07 to 21.48); P=0.04 | 1.06 (0.20 to 5.51); P=0.9 |
| Direct | — | — | — | NA | NA | NA |
| Network | — | — | — | 0.78 (0.29 to 2.07); P=0.6 | 2.62 (0.52 to 13.23); P=0.2 | 0.58 (0.12 to 2.79); P=0.5 |
| Direct | — | — | — | — | NA | NA |
| Network | — | — | — | — | 3.37 (0.56 to 20.39); P=0.2 | 0.74 (0.13 to 4.25); P=0.7 |
| Direct | — | — | — | — | — | NA |
| Network | — | — | — | — | — | 0.22 (0.03 to 1.95); P=0.2 |
NA=not available
*I2=4%
†I2=not applicable, only one study in comparison.
‡I2 =0%.

Fig 4 Trends in types of endometrial ablation procedures performed in England, 2004-11 (data from hospital episode statistics)